SMC accepts clostridium botulinum toxin A (DysportT) for restricted use in patients with focal spasticity

Source: Scottish Medicines Consortium (SMC) Area: Evidence > Drug Specific Reviews The Scottish Medicines Consortium has accepted clostridium botulinum type A toxin-haemagglutinin complex (DysportT)  for restricted use within NHS Scotland for the treatment of focal spasticity of the upper limbs associated with stroke.   The drug advice (see link below) summarises the safety and efficacy data considered for this drug in this indication. This notes that clostridium botulinum type A toxin-haemagglutinin complex (Dysport®) produces a localised reduction in muscle tone in patients with post-stroke upper limb spasticity and can improve patient disability at 16 weeks. It continues to be effective after repeated administrations with no new adverse events apparent.   Please see the link below for further details.
Source: NeLM - Drug Specific Reviews - Category: Drugs & Pharmacology Source Type: news